Eargo, Inc. (Nasdaq: EAR) (“Eargo” or the “Company”), a medical
device company on a mission to improve hearing health, today
reported its financial results for the second quarter ended June
30, 2023.
William Brownie, Interim CEO and COO, said, “Through the first
half of 2023, we made incremental progress on our key retail,
insurance, and innovation initiatives as we continue to evolve
Eargo into a true omni-channel business. While each of these
initiatives will take time to fully implement and refine, we are
pleased that with each quarter we have made progress on that
evolution.”
“Our core direct-to-consumer cash-pay segment has been stable
through 2023 as compared to 2022. We continue to focus on lowering
customer acquisition costs through further optimizing media spend
and maintaining an efficient inside sales force. Meanwhile, demand
from consumers interested in purchasing Eargo devices through our
evolving retail channel continues to develop following our launch
in Victra’s approximately 1,500 retail locations nationwide and the
FDA’s over-the-counter final rule. As expected, retail shipment
volume was lower sequentially in the second quarter, following the
large stocking order by Victra following the launch of Eargo 7 in
the first quarter. We see continued value in our partnership and
are committed to this important sales channel as part of our
omni-channel strategy. We anticipate that our insurance channels
will be a priority of the Company as we continue to work with
payors to establish coverage for Eargo and to establish
relationships with health plans, benefits managers, and managed
care providers following the OTC final rule.”
Mr. Brownie concluded, “As part of our previously announced cost
reduction plan, we are taking steps to further streamline our
business and significantly reduce cash burn to provide an extended
runway to execute our omni-channel strategy. While this difficult
decision will result in a reduced overall workforce, we plan to
maintain top talent across key functions, which we believe will
allow us to continue to satisfy consumer demand across our
omni-channel and support existing customers as well as support our
insurance channel strategy and innovation priorities. The cost
reduction plan is expected to reduce our go-forward cash burn
estimates, and we anticipate this reduced burn rate will extend our
net operating cash runway into the second half of 2024. Lastly,
Christian Gormsen, Eargo’s CEO for seven years, departed from the
Company in June. On behalf of the entire Eargo organization, I want
to thank Christian for his many contributions over the years and
wish him well in his new endeavors.”
Second Quarter 2023 Financial and
Operating Results
During the second quarter of 2023, we announced
a cost reduction plan intended to optimize our cost structure and
operating model. We currently expect the cost reduction plan to be
substantially implemented through the end of fiscal 2023 and
estimate that we will incur one-time charges of approximately $3.5
million to $5.0 million in connection with the plan. The majority
of the costs we expect to incur in connection with the cost
reduction plan will be recorded as they are incurred and are
therefore not reflected in the discussion below.
Gross systems shipped for the second quarter of 2023 were 5,098,
compared to 4,455 during the second quarter of 2022. The
year-over-year increase in shipment volume was largely driven by
sales of our Eargo hearing aids to Victra, our largest retail
partner, for in-person customer sales at its approximately 1,500
store locations across the United States. We are currently unable
to predict the timing or size of any future Victra orders, which
may impact our net revenue and the consistency of our results on a
sequential and quarterly basis.
The sales returns rate for the second quarter of 2023 was 34.2%,
compared to 33.3% in the second quarter of 2022. The year-over-year
increase in the sales returns rate in the second quarter of 2023
was primarily due to a higher sales returns rate for systems sold
to Victra.
Net revenue was $8.1 million for the second
quarter of 2023, compared to $7.2 million for the second quarter of
2022. The year-over-year increase was driven by the increase in
gross systems shipped.
Gross profit for the second quarter of 2023 was
$1.6 million, compared to gross profit of $2.5 million for the
second quarter of 2022. Gross margin was 20.1% for the second
quarter of 2023, compared with 34.7% for the second quarter of
2022. The year-over-year decrease in gross margin was primarily due
to rework costs of $0.8 million to address loss of charging
capacity in certain of our hearing aids in inventory and impairment
charges of $0.8 million related to previously capitalized software
costs, which, when combined, reduced gross margins in the second
quarter of 2023 by approximately 20%.
Total operating expenses were $27.4 million, or
338.4% of net revenues, for the second quarter of 2023, compared
with $34.0 million, or 468.6%, for the second quarter of 2022.
Sales and marketing expenses were $12.6 million,
or 155.7% of net revenues, for the second quarter of 2023, compared
with $12.7 million, or 175.7%, for the second quarter of 2022.
Lower media spend in the second quarter of 2023 compared to the
corresponding prior-year period was offset by increases in
personnel and personnel-related costs.
Research and development expenses were $5.4
million, or 66.2% of net revenues, for the second quarter of 2023,
compared with $3.9 million, or 53.5%, for the second quarter of
2022. The year-over-year increase was primarily driven by higher
personnel-related costs, partially offset by lower third-party
costs.
General and administrative expenses were $9.4
million, or 116.5% of net revenues, for the second quarter of 2023,
compared with $17.3 million, or 239.3%, for the second quarter of
2022. The year-over-year decrease was primarily driven by a
reduction in general corporate costs related to legal, consulting
and other professional fees that were driven by activities related
to litigation, financing and compliance matters in the second
quarter of 2022. The decrease in general and administrative expense
also includes a net increase in personnel and personnel-related
costs of $1.1 million, which includes a $0.5 million increase in
headcount and a $1.6 million increase related to employee workforce
reduction costs for severance and related benefits, partially
offset by a $1.0 million credit related to the reversal of
previously expensed stock-based compensation associated with
forfeited equity awards.
Excluding stock-based compensation expense,
non-GAAP operating expenses for the second quarter of 2023 were
$24.9 million, including research and development expenses of $4.7
million, sales and marketing expenses of $11.6 million, and general
and administrative expenses of $8.7 million. Please refer to the
section below titled “Use of Non-GAAP Financial Measures” and the
non-GAAP reconciliation tables at the end of this press
release.
GAAP loss from operations was $25.8 million, or
318.3% of net revenues, for the second quarter of 2023, compared
with $31.4 million, or 433.9% of net revenues, for the second
quarter of 2022. The year-over-year decrease in GAAP loss from
operations was primarily due to factors described in the above
paragraphs. Excluding stock-based compensation expense, non-GAAP
loss from operations losses for the second quarter of 2023 were
$23.2 million, compared with $30.0 million in the second quarter of
2022.
Net loss attributable to common stockholders for
the second quarter of 2023 was $25.2 million, or $1.21 per share,
compared to a net loss attributable to common stockholders of $32.4
million, or $16.48 per share, for the second quarter of 2022.
Excluding stock-based compensation expense, non-GAAP net loss
attributable to common stockholders for the second quarter of 2023
was $22.5 million, or $1.08 per share, compared to a non-GAAP net
loss of $30.9 million, or $15.71 per share, for the same period in
2022. The year-over-year decrease in both GAAP and non-GAAP net
loss per share attributable to common stockholders was primarily
driven by a reduction in GAAP and non-GAAP net loss, respectively,
and the Company’s rights offering and related conversion of senior
secured convertible notes completed in November 2022, which
resulted in the issuance of 18.75 million additional shares of our
common stock.
Net operating cash burn, defined as cash used in
operating and investment activities, for the second quarter of 2023
was approximately $19.0 million.
Cash and cash equivalents were $60.8 million as
of June 30, 2023, compared to $101.2 million as of December 31,
2022.
2023 Financial GuidanceThe
Company is not providing financial guidance at this time.
Conference Call and Webcast
InformationThe Company will not be hosting a conference
call and webcast to discuss second quarter 2023 results.
About EargoEargo is a medical
device company on a mission to improve hearing health. Our
innovative products and go-to-market approach address the major
challenges of traditional hearing aid adoption, including social
stigma, accessibility and cost. We believe our Eargo hearing aids
are the first virtually invisible, rechargeable,
completely-in-canal, FDA-regulated devices indicated to compensate
for mild to moderate hearing loss. Our differentiated,
consumer-first approach empowers consumers to take control of their
hearing. Consumers can purchase online, at retail locations or over
the phone and get personalized and convenient consultation and
support from hearing professionals via phone, text, email or video
chat. Eargo hearing aids are offered to consumers at approximately
half the cost of competing hearing aids purchased through
traditional channels in the United States.
Eargo’s seventh generation device, Eargo 7, is
an FDA 510(k) cleared, self-fitting over-the-counter hearing aid
featuring Sound Adjust+ with Comfort and Clarity Modes, which
focuses on noise reduction and adapting to the user’s environment
and needs. Eargo 7 is available for purchase here.
Related Linkshttp://eargo.com
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements other
than statements of historical fact contained in this press release
are forward-looking statements, including but not limited to
statements regarding the continued evolution of our omni-channel
business; consumer demand for our products and our ability to
satisfy demand; the efficiency of our customer acquisition and
media spend; our partnerships with Victra and other third-party
partners; our work with payors to establish insurance coverage for
our products and to establish relationships with health plans,
benefits managers, and managed care providers; the effects, timing
and costs of our cost reduction plans; our ability to support our
customers; our strategy and innovation priorities; and our expected
net operating cash runway. Forward-looking statements are not
guarantees of future performance and are subject to risks,
uncertainties and assumptions that could cause actual results and
events to differ materially from those anticipated, including, but
not limited to, risks, uncertainties and assumptions related to:
our expectations regarding our omni-channel business, including
partnerships with retailers, resellers and other distributors
(whether brick and mortar or online); the extent to which we may be
able to validate and establish processes to support the submission
of claims for reimbursement from third-party payors or to otherwise
establish relationships with health plans, benefits managers, and
managed care providers, and our ability to maintain or increase
insurance coverage of our hearing aids; the timing or results of
ongoing claims audits and medical records reviews by third-party
payors; estimates of our future capital needs and our ability to
raise capital on favorable terms, if at all, including the timing
of future capital requirements and the terms or timing of any
future financings; the effects, timing and costs of our cost
reduction plans; the impact of the regulatory landscape for hearing
aid devices on our business and results of operations; our
expectations concerning additional orders by existing customers;
our expectations regarding the potential market size and size of
the potential consumer populations for our products and any future
products, including insurance coverage of our hearing aids; our
ability to release new hearing aids and the anticipated features of
any such hearing aids; the performance, differentiation and
attractiveness to consumers of our products; developments and
projections relating to our competitors and our industry, including
competing products; our ability to maintain our competitive
technological advantages against new entrants in our industry; the
pricing of our hearing aids; our expectations regarding the ability
to make certain claims related to the performance of our hearing
aids relative to competitive products; our expectations with regard
to changes in the regulatory landscape for hearing aid devices and
related opportunities, including the implementation and effects of
the new over-the-counter hearing aid regulatory framework; and our
expectations regarding macroeconomic conditions, including but not
limited to the impact of COVID-19, inflationary trends, uncertainty
or volatility in the market (including recent and potential
disruption in the banking system and financial markets and
geopolitical events (such as the conflict in Ukraine and tensions
across the Taiwan Strait)) on our business and results of
operations. These and other risks are described in greater detail
in the sections titled “Risk Factors” contained in our Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q and in our
other filings with the Securities and Exchange Commission. Any
forward-looking statements in this press release are made pursuant
to the Private Securities Litigation Reform Act of 1995, as
amended, are based on current expectations, forecasts and
assumptions, and speak only as of the date of this press release.
Except as required by law, we undertake no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Use of Non-GAAP Financial
MeasuresThe Company reports non-GAAP results for gross
profit, gross margin, total operating expenses, sales and marketing
expenses, research & development expenses, general &
administrative expenses, total operating loss, net loss, and net
loss per share in addition to, and not as a substitute for, or
superior to, financial measures calculated in accordance with GAAP.
The Company’s financial measures under GAAP include charges such as
stock-based compensation, as listed in the itemized reconciliations
between GAAP and non-GAAP financial measures included in this press
release. Management has excluded the effects of stock-based
compensation in its non-GAAP financial measures to assist investors
in analyzing and assessing the Company’s operating performance. In
addition, these non-GAAP financial measures are not based on any
comprehensive set of accounting rules or principles, and they may
not be comparable with similarly named financial measures of other
companies. The Company encourages investors to carefully consider
its results under GAAP, as well as its supplemental non-GAAP
financial measures and the reconciliation between these
presentations, to more fully understand its business.
Investor ContactAdam LaponisChief Financial
Officerir@eargo.com
Eargo,
Inc.Consolidated Balance Sheets
(Unaudited) (In thousands, except share
and per share amounts) |
|
|
June 30, |
|
December 31, |
|
|
|
2023 |
|
|
|
2022 |
|
ASSETS |
|
|
|
|
Current
assets: |
|
|
|
|
Cash and cash equivalents |
|
$ |
60,779 |
|
|
$ |
101,238 |
|
Accounts receivable, net |
|
|
961 |
|
|
|
1,910 |
|
Inventories |
|
|
5,360 |
|
|
|
5,036 |
|
Prepaid expenses and other current assets |
|
|
5,835 |
|
|
|
7,846 |
|
Total
current assets |
|
|
72,935 |
|
|
|
116,030 |
|
Operating
lease right-of-use assets |
|
|
7,582 |
|
|
|
5,765 |
|
Property and
equipment, net |
|
|
4,586 |
|
|
|
7,441 |
|
Intangible
assets, net |
|
|
850 |
|
|
|
1,063 |
|
Goodwill |
|
|
873 |
|
|
|
873 |
|
Other
assets |
|
|
724 |
|
|
|
906 |
|
Total
assets |
|
$ |
87,550 |
|
|
$ |
132,078 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
Current
liabilities: |
|
|
|
|
Accounts payable |
|
$ |
3,729 |
|
|
$ |
6,504 |
|
Accrued expenses |
|
|
9,665 |
|
|
|
12,715 |
|
Sales returns reserve |
|
|
5,070 |
|
|
|
3,942 |
|
Other current liabilities |
|
|
1,457 |
|
|
|
1,462 |
|
Lease liability, current portion |
|
|
602 |
|
|
|
628 |
|
Total
current liabilities |
|
|
20,523 |
|
|
|
25,251 |
|
Lease
liability, noncurrent portion |
|
|
7,210 |
|
|
|
5,973 |
|
Total
liabilities |
|
|
27,733 |
|
|
|
31,224 |
|
Stockholders’ equity: |
|
|
|
|
Preferred
stock, $0.0001 par value per share; 5,000,000 shares authorized as
of June 30, 2023 and December 31, 2022, respectively; zero shares
issued and outstanding as of June 30, 2023 and December 31, 2022,
respectively |
|
|
— |
|
|
|
— |
|
Common
stock; $0.0001 par value; 450,000,000 shares authorized as of June
30, 2023 and December 31, 2022, respectively; 20,749,579 and
20,726,965 shares issued and outstanding as of June 30, 2023 and
December 31, 2022, respectively |
|
|
2 |
|
|
|
2 |
|
Additional
paid-in capital |
|
|
621,188 |
|
|
|
615,151 |
|
Accumulated
deficit |
|
|
(561,373 |
) |
|
|
(514,299 |
) |
Total
stockholders’ equity |
|
|
59,817 |
|
|
|
100,854 |
|
Total
liabilities and stockholders’ equity |
|
$ |
87,550 |
|
|
$ |
132,078 |
|
|
|
|
|
|
Eargo,
Inc.Consolidated Statements of Operations and
Comprehensive Loss (Unaudited)
(In thousands, except share and per share
amounts) |
|
|
Three months ended June 30, |
|
Six Months Ended June 30, |
|
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Revenue,
net |
|
$ |
8,108 |
|
|
$ |
7,247 |
|
|
$ |
19,921 |
|
|
$ |
16,423 |
|
Cost of
revenue |
|
|
6,477 |
|
|
|
4,733 |
|
|
|
13,168 |
|
|
|
10,224 |
|
Gross profit
(loss) |
|
|
1,631 |
|
|
|
2,514 |
|
|
|
6,753 |
|
|
|
6,199 |
|
Operating
expenses: |
|
|
|
|
|
|
|
|
Research and development |
|
|
5,364 |
|
|
|
3,879 |
|
|
|
9,969 |
|
|
|
9,726 |
|
Sales and marketing |
|
|
12,627 |
|
|
|
12,734 |
|
|
|
26,028 |
|
|
|
26,024 |
|
General and administrative |
|
|
9,446 |
|
|
|
17,344 |
|
|
|
19,354 |
|
|
|
32,278 |
|
Total
operating expenses |
|
|
27,437 |
|
|
|
33,957 |
|
|
|
55,351 |
|
|
|
68,028 |
|
Loss from
operations |
|
|
(25,806 |
) |
|
|
(31,443 |
) |
|
|
(48,598 |
) |
|
|
(61,829 |
) |
Other income
(expense), net: |
|
|
|
|
|
|
|
|
Interest income |
|
|
654 |
|
|
|
56 |
|
|
|
1,524 |
|
|
|
61 |
|
Interest expense |
|
|
— |
|
|
|
(285 |
) |
|
|
— |
|
|
|
(549 |
) |
Loss on extinguishment of debt |
|
|
— |
|
|
|
(772 |
) |
|
|
— |
|
|
|
(772 |
) |
Total other
income (expense), net |
|
|
654 |
|
|
|
(1,001 |
) |
|
|
1,524 |
|
|
|
(1,260 |
) |
Loss before
income taxes |
|
|
(25,152 |
) |
|
|
(32,444 |
) |
|
|
(47,074 |
) |
|
|
(63,089 |
) |
Income tax
provision |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Net loss and
comprehensive loss |
|
$ |
(25,152 |
) |
|
$ |
(32,444 |
) |
|
$ |
(47,074 |
) |
|
$ |
(63,089 |
) |
Net income
(loss) attributable to common stockholders, basic and diluted |
|
$ |
(25,152 |
) |
|
$ |
(32,444 |
) |
|
$ |
(47,074 |
) |
|
$ |
(63,089 |
) |
Net income
(loss) per share attributable to common stockholders, basic and
diluted |
|
$ |
(1.21 |
) |
|
$ |
(16.48 |
) |
|
$ |
(2.27 |
) |
|
$ |
(32.07 |
) |
Weighted-average shares used in computing net income (loss) per
share attributable to common stockholders, basic and diluted |
|
|
20,745,838 |
|
|
|
1,968,201 |
|
|
|
20,740,152 |
|
|
|
1,967,175 |
|
|
|
|
|
|
|
|
|
|
Eargo, Inc. Results of Operations –
Reconciliation between GAAP and Non-GAAP
(Unaudited) (In thousands, except per
share amounts) |
|
|
|
|
|
|
|
|
Reconciliation
between GAAP and non-GAAP net loss per share attributable to common
stockholders: |
|
Three months ended June 30, |
|
Six Months Ended June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
GAAP net
loss per share to common stockholders, basic and diluted |
$ |
(1.21 |
) |
|
$ |
(16.48 |
) |
|
$ |
(2.27 |
) |
|
$ |
(32.07 |
) |
Stock-based compensation |
|
0.13 |
|
|
|
0.77 |
|
|
|
0.29 |
|
|
|
2.31 |
|
Non-GAAP net
loss per share to common stockholders, basic and diluted |
$ |
(1.08 |
) |
|
$ |
(15.71 |
) |
|
$ |
(1.98 |
) |
|
$ |
(29.76 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation
between GAAP and non-GAAP net loss attributable to common
stockholders: |
|
Three months ended June 30, |
|
Six Months Ended June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
GAAP net
loss attributable to common stockholders, basic and diluted |
$ |
(25,152 |
) |
|
$ |
(32,444 |
) |
|
$ |
(47,074 |
) |
|
$ |
(63,089 |
) |
Stock-based compensation |
|
2,629 |
|
|
|
1,511 |
|
|
|
6,037 |
|
|
|
4,535 |
|
Non-GAAP net
loss attributable to common stockholders, basic and diluted |
$ |
(22,523 |
) |
|
$ |
(30,933 |
) |
|
$ |
(41,037 |
) |
|
$ |
(58,554 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation
between GAAP and non-GAAP gross profit and gross
margin: |
|
Three months ended June 30, |
|
Six Months Ended June 30, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
GAAP
gross profit |
$ |
1,631 |
|
|
$ |
2,514 |
|
|
$ |
6,753 |
|
|
$ |
6,199 |
|
Stock-based compensation |
|
48 |
|
|
|
37 |
|
|
|
90 |
|
|
|
59 |
|
Non-GAAP
gross profit |
$ |
1,679 |
|
|
$ |
2,551 |
|
|
$ |
6,843 |
|
|
$ |
6,258 |
|
|
|
|
|
|
|
|
|
GAAP
gross margin |
|
20.1 |
% |
|
|
34.7 |
% |
|
|
33.9 |
% |
|
|
37.7 |
% |
Stock-based compensation |
|
0.6 |
% |
|
|
0.6 |
% |
|
|
0.5 |
% |
|
|
0.4 |
% |
Non-GAAP
gross margin |
|
20.7 |
% |
|
|
35.3 |
% |
|
|
34.4 |
% |
|
|
38.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation
between GAAP and non-GAAP operating expenses and operating
loss: |
|
Three months ended June 30, |
|
Six Months Ended June 30, |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
GAAP
research and development expense |
$ |
5,364 |
|
|
$ |
3,879 |
|
|
$ |
9,969 |
|
|
$ |
9,726 |
|
Stock-based compensation |
|
(714 |
) |
|
|
585 |
|
|
|
(1,366 |
) |
|
|
(435 |
) |
Non-GAAP
research and development expense |
$ |
4,650 |
|
|
$ |
4,464 |
|
|
$ |
8,603 |
|
|
$ |
9,291 |
|
|
|
|
|
|
|
|
|
GAAP
sales and marketing expense |
$ |
12,627 |
|
|
$ |
12,734 |
|
|
$ |
26,028 |
|
|
$ |
26,024 |
|
Stock-based compensation |
|
(1,075 |
) |
|
|
(693 |
) |
|
|
(1,965 |
) |
|
|
(1,333 |
) |
Non-GAAP
sales and marketing expense |
$ |
11,552 |
|
|
$ |
12,041 |
|
|
$ |
24,063 |
|
|
$ |
24,691 |
|
|
|
|
|
|
|
|
|
GAAP
general and administrative expense |
$ |
9,446 |
|
|
$ |
17,344 |
|
|
$ |
19,354 |
|
|
$ |
32,278 |
|
Stock-based compensation |
|
(792 |
) |
|
|
(1,366 |
) |
|
|
(2,616 |
) |
|
|
(2,708 |
) |
Non-GAAP
general and administrative expense |
$ |
8,654 |
|
|
$ |
15,978 |
|
|
$ |
16,738 |
|
|
$ |
29,570 |
|
|
|
|
|
|
|
|
|
GAAP
total operating expense |
$ |
27,437 |
|
|
$ |
33,957 |
|
|
$ |
55,351 |
|
|
$ |
68,028 |
|
Stock-based compensation |
|
(2,581 |
) |
|
|
(1,474 |
) |
|
|
(5,947 |
) |
|
|
(4,476 |
) |
Non-GAAP
total operating expense |
$ |
24,856 |
|
|
$ |
32,483 |
|
|
$ |
49,404 |
|
|
$ |
63,552 |
|
|
|
|
|
|
|
|
|
GAAP
operating loss |
$ |
(25,806 |
) |
|
$ |
(31,443 |
) |
|
$ |
(48,598 |
) |
|
$ |
(61,829 |
) |
Stock-based compensation |
|
2,629 |
|
|
|
1,511 |
|
|
|
6,037 |
|
|
|
4,535 |
|
Non-GAAP
operating loss |
$ |
(23,177 |
) |
|
$ |
(29,932 |
) |
|
$ |
(42,561 |
) |
|
$ |
(57,294 |
) |
|
|
|
|
|
|
|
|
Eargo (NASDAQ:EAR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eargo (NASDAQ:EAR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024